Figure 6 | Scientific Reports

Figure 6

From: Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment

Figure 6The alternative text for this image may have been generated using AI.

FCGBP expression as a potential predictor for drug sensitivity. (A) The compound activity z scores of chosen compounds in relation to FCGBP expression, as shown by correlation analysis. (B) Correlation analysis using the Spearman correlation test for FCGBP expression and activity z scores of cisplatin, docetaxel, paclitaxel, carboplatin, 5-fluoro deoxy uridine 10mer, methotrexate, fluorouracil, and gemcitabine. (C) Activity z scores of paclitaxel in the high FCGBP expression group compared with those in the low FCGBP expression group. (D) IC50 values of chemotherapeutics, including paclitaxel, cisplatin, docetaxel, methotrexate, and gemcitabine in the high FCGBP expression HNSC cell lines compared with those in the low FCGBP expression HNSC patients. HNSC cell lines with low FCGBP expression were found to possess higher IC50 for drugs. The p-values were calculated using the Wilcoxon rank-sum test.

Back to article page